IQVIA
85,486 employees on LinkedIn Β· Public Β· 2 known investors
IQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Also known as IQV Β· IQVIA Holdings Inc. Β· QuintilesIMS
Investors Β· 2
Company profile
researched Aug 2026IQVIA is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries. Its offerings span research and development (clinical trials, functional service provision, patient engagement in clinical research, consulting), real world evidence (real world and healthcare data, study design, evidence networks in areas such as oncology, neurology and immunology, health economics and value), commercialization (launch strategy and management, brand and portfolio strategy, pricing and market access, patient engagement and support, omnichannel engagement), and safety and regulatory compliance (drug safety and pharmacovigilance, regulatory compliance, quality compliance and commercial compliance).
The company markets its combined data, analytics, technology and domain expertise under the IQVIA Connected Intelligence banner and offers therapeutic specialization through 18 Therapeutic Centers of Excellence covering oncology and hematology, rare diseases, central nervous system, infectious diseases and vaccines, gastroenterology and hepatology, diabetes, pediatrics and biosimilars. Newer models and methods include IQVIA AI, virtual/decentralized research, genomics and digital health. IQVIA Biotech delivers full-service clinical development for smaller sponsors, and industry-segment offerings target pharmaceutical manufacturers, emerging biopharma, consumer health, generics manufacturers, information partners such as pharmacies and wholesalers, government, patient associations, payers and providers.
IQVIA also operates the IQVIA Institute for Human Data Science, which publishes research on medicine use, R&D trends, oncology, biosimilars and digital health based on non-identified patient-level data, including reports such as Global Medicine Use Trends 2026, U.S. Medicine Use Trends 2026 and Global R&D Trends 2026.
Founding story
IQVIA's predecessors were founded by Bill Frohlich and David Dubow, who established IMS Health in 1954 to systematically collect and analyze pharmaceutical sales data, and by biostatistician Dennis Gillings, who started Quintiles in 1982 as a biostatistics consulting venture in North Carolina that grew into a contract research organization.
Business model
IQVIA sells data, analytics, technology platforms and outsourced services to life sciences and healthcare organizations, combining information assets (such as prescription and sales data and non-identified patient records) with consulting, clinical development services and software across the product lifecycle.
Revenue is generated from data and analytics subscriptions and licensing, technology solutions, consulting engagements, and contracted clinical development, real world evidence, safety, regulatory and commercial services.
Traction
IQVIA reports more than 68 petabytes of proprietary data, over 1.2 billion non-identified patient records, coverage of 85% of global pharma sales, more than 13,000 technology experts, and 46% faster clinical trial site identification. It cites experience from more than 5,000 product launches and more than 245 rare disease studies across 96 countries. By the mid-2020s the company reported annual revenues in the range of $15 billion.
Latest developments
IQVIA announced a partnership with NVIDIA to accelerate Healthcare-grade AI and unveiled IQVIA.ai, a unified agentic AI platform powered by NVIDIA, alongside new AI agents for life sciences and healthcare. It also announced a strategic long-term global commercial data foundation transformation collaboration with Boehringer Ingelheim, was ranked No. 1 Pharmaceutical Technology Provider by Everest Group, and was named a 2026-2027 Best Company to Work For by U.S. News & World Report. The IQVIA Institute published its Global Medicine Use Trends 2026, U.S. Medicine Use Trends 2026 and Global R&D Trends 2026 reports.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
IQVIA describes itself as a leading global provider of advanced analytics, technology solutions and clinical research services to life sciences, and states it tracks 85% of global pharma sales. It was ranked No. 1 Pharmaceutical Technology Provider by Everest Group and included in the Fortune World's Most Admired Companies list for 2026, its ninth consecutive year, ranking first in the Health Care: Pharmacy and Other Services category. Its predecessor Quintiles was recognized as the world's largest CRO by the mid-2010s.
The company positions the integration of large-scale proprietary healthcare data, analytics, technology and domain expertise β marketed as Connected Intelligence β across the full lifecycle from clinical development through commercialization, supported by privacy-enhancing technologies for handling non-identified patient data and a therapeutic-area specialist model.
Technology
IQVIA combines proprietary healthcare data assets with analytics and what it markets as Healthcare-grade AI. It has introduced IQVIA.ai, a unified agentic AI platform powered by NVIDIA, along with AI agents including the Field Force Agent for field-team HCP engagement built on IQVIA OneKey HCP/HCO reference data, and the Global Market Insights (GMI) Agent for market landscape analysis, competitive intelligence, pipeline analysis, loss-of-protection timelines and forecasts. Other capabilities include machine learning-driven commercial analytics, genomics at scale with privacy preservation, decentralized/virtual trials and the Human Data Science Cloud.
Go-to-market
Direct enterprise sales and consulting engagements organized by solution area (research and development, real world evidence, commercialization, safety and regulatory compliance, technologies) and by industry segment, supported by thought-leadership research from the IQVIA Institute and customer events such as TechIQ 2026 in Boston (October 7-8).
Pharmaceutical, biotech and medical device manufacturers, emerging biopharma, generics and consumer health companies, pharmacies and wholesalers, government agencies, patient associations, payers, providers and medical researchers.
Geography
Operations in more than 100 countries, with corporate headquarters at 2400 Ellis Rd, Durham, North Carolina, and country- and region-specific websites.
History
IQVIA was formed from the merger of IMS Health and Quintiles. IMS Health was founded in 1954 in New York as Intercontinental Medical Statistics, focused on pharmaceutical market research and data analytics, and became a publicly traded healthcare information company after a period of private ownership from 2010 to 2014. Quintiles was founded in 1982 by Dennis Gillings in North Carolina, grew into one of the largest contract research organizations, acquired Innovex in 1996, went public in 1997, went private in 2003 and re-listed on the NYSE in 2013. The two companies announced a merger of equals in 2016, valued at roughly $9 billion; the deal closed in October 2016 creating QuintilesIMS, which rebranded as IQVIA in November 2017 and trades on the NYSE as IQV. The company subsequently made acquisitions in real-world evidence, artificial intelligence and healthcare marketing software, and took full control of its Q2 Solutions lab joint venture.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Founder mafia
The IQVIA mafia β9 people who came through IQVIA went on to found or lead other companies.
Timeline Β· 11
launches, deals, and filingsIQVIA was included in the Fortune World's Most Admired Companies list for 2026, its ninth consecutive year, and ranked first in the Health Care: Pharmacy and Other Services category for the fifth time.
IQVIA and Boehringer Ingelheim announced a strategic long-term global commercial data foundation transformation collaboration.
IQVIA announced a collaboration with NVIDIA intended to create new ways for customers to accelerate efforts to improve patient outcomes.
New agentic AI products announced include the Field Force Agent for field-team HCP engagement and the Global Market Insights (GMI) Agent for market landscape analysis.
IQVIA announced IQVIA.ai, a unified agentic AI platform powered by NVIDIA, aimed at improving efficiency and decision making across life sciences.
In November 2017 the combined company rebranded as IQVIA and began trading on the NYSE under the ticker IQV, led by Chairman and CEO Ari Bousbib.
IMS Health and Quintiles announced a merger of equals in 2016 valued at roughly $9 billion; the deal closed in October 2016 and the combined company was initially named QuintilesIMS.
$9B source β
IQVIA fully acquired control of its lab joint venture, Q2 Solutions, to strengthen lab testing services.
Predecessor company Quintiles acquired Innovex in 1996 to add pharmaceutical salesforce and marketing services.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 8
primary sources listed
- IQVIAiqvia.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does IQVIA do?
- IQVIA is a global provider of healthcare data, analytics, technology and clinical research services to the life sciences industry.
- Who are IQVIA's investors?
- IQVIA's investors include Leonard Green, TPG.